Check the claim behind the treatment

Match the evidence to the proposal

When a treatment page points to a study, ask what was actually studied. Was it the ingredient, form and purpose now being offered? Ask which result matters to the problem you want to discuss. A study title alone leaves those questions unanswered.

Request the full source rather than only a sentence from an advertisement. Ask the clinician—the health professional considering your treatment—to separate what the evidence shows from what remains uncertain. If the proposal uses a blend, ask what evidence addresses that particular combination.

A code in a public record can be misread too. NDC is the short form used for National Drug Code, a product identifier in Food and Drug Administration (FDA) records.

As of November 3, 2026, the FDA says that receiving an NDC does not establish approval; listing information is not the same as the agency reviewing a medicine.

Compounding means a pharmacist, doctor or registered facility—a business signed up with the FDA—makes a medicine to meet a need.

The FDA oversees those registered facilities; state pharmacy boards have day-to-day oversight of ordinary compounding pharmacies.

For compounding, ask which ingredient rule and which pharmacy apply. For an approved medicine, ask for its current labeling. For a study claim, ask for the actual study and the limits of its findings. These are requests for different kinds of proof.

Read the HHS draft within its limits

The federal health department published the peptide-compounding draft on October 30, 2026. Its full name is the Department of Health and Human Services (HHS).

It concerns state-licensed pharmacies and physicians. If its conditions are met, HHS says it does not plan to take enforcement action over making medicine for a named patient’s prescription. This describes the government’s intended response; it does not make compounding lawful.

The draft covers single-ingredient preparations of KPV, TB-500 and semax, as well as MOTS-c, epitalon and BPC-157. None of these peptides is FDA-approved. Its conditions limit both the chemical form—the exact version of the ingredient itself—and how it is given, such as by mouth or injection.

This is the patient-specific route known as section 503A, named for its part of federal law.

Blends are outside this draft, as are facilities operating under section 503B.

Section 503B is the separate federal route for registered facilities that prepare batches of medicines free of living germs.

The draft and its attached sections, called appendices, list the conditions. Ask the prescriber to check the exact ingredient version and the way it would be given against those sections. The draft does not require HHS to follow it, and it gives no one a right to compound.

As of November 3, 2026, this draft gives those peptides no FDA approval and adds none to the official 503A ingredient list.

That list identifies extra raw ingredients permitted in medicines made for individual patients. It is one of the ways an ingredient can qualify for this kind of compounding; the other requirements still apply.

HHS says the advisory panel voted in favor of those six peptides at its July 2026 meeting.

An advisory vote informs the agency; the vote itself does not change the ingredient rules.

Nevada’s rules on ingredients still apply. The federal draft does not set aside state law.

For a Nevada proposal, ask the prescriber to identify the specific preparation and the basis for using it. “A draft exists” leaves too much unsaid. Ask how the plan fits its conditions and the state rules, rather than treating a headline as the whole answer.

A withdrawn request is not clearance

FDA dates its raw-ingredient page April 22, 2026. On that page, withdrawn requests remain listed beside the agency’s safety concerns.

Those groups had asked FDA to add raw ingredients to the 503A list for making medicines for individual patients. They took those requests back; FDA did not clear the ingredients.

FDA does not date each withdrawal in the table. April 22, 2026 dates the page; it does not tell you when an ingredient entered the withdrawn-requests table.

Keep the withdrawn-request table separate from the later HHS draft. If someone points to either document, ask which exact entry applies. Then ask what the document leaves unresolved. That is more useful than a broad claim that peptides became allowed.

Research labels do not answer the care question

As of November 3, 2026, FDA warns against research-labeled weight-loss drugs sold for human use, citing unknown quality and possible harm.

FDA uses a seller’s claims about treating people to decide whether a product is being offered as a drug for human use. A research-only label does not undo those claims.

Keep that label in view when asking what is being offered. Ask for the finished medicine’s name, who prescribes it and which pharmacy dispenses it. If the answer sends you back to a list of chemicals, the original care question is still open.

Check claims of sameness

A national shortage once allowed pharmacies to make versions of semaglutide and tirzepatide injections under a shortage exception. One nearby pharmacy running out of stock does not reopen that exception.

FDA records checked November 3, 2026 show neither medicine in national shortage.

Nevada’s pharmacy board issued a notice on June 2, 2025 telling pharmacies to stop relying on the shortage exception to make copies of these injections. It also pointed to federal exceptions that can still apply to a particular preparation.

The Nevada notice does not amount to a ban on every compounded preparation.

A prescriber may find that changing a ready-made medicine makes an important difference for one named patient’s care. That difference can mean federal law does not count the preparation as a copy.

For example, discuss a dye allergy and whether that dye needs to be left out of the medicine.

Ask what that difference is in the proposed care. A lower price and a familiar ingredient name do not answer the question. Request the reasoning in plain words, then keep it with the product and pharmacy names.

Know where a concern belongs

FDA has reported errors in measuring compounded semaglutide, including reports that involved hospitalization, in its safety information checked November 3, 2026.

Ask the prescribing clinician or the pharmacist supplying the medicine about any unclear measuring instructions, including switching between the medicine’s amount and syringe markings. This guide does not work out those measurements. Ask who can answer a product question and how to reach them.

In its severe-allergy advice, MedlinePlus directs a call to 911. Tongue swelling and breathing difficulty are among the symptoms it names.

A medicine concern can also be reported by a patient through FDA MedWatch, the agency’s safety-reporting program.

A submitted account alone cannot show that a drug was to blame.

For a Nevada licensing concern, use the board that oversees the person or pharmacy. The medical board’s complaint page takes complaints about doctors with an MD degree. The osteopathic board takes complaints about DO doctors; DO is the degree called Doctor of Osteopathic Medicine. Physician assistants’ complaints go to the board that issued their license.

The nursing board accepts nursing complaints, while the pharmacy board handles pharmacy complaints rather than billing or price disputes.